The call presents a predominantly positive outlook with significant regulatory and commercial progress for apitegromab, supported by strong financials and positive clinical trial results. However, there are challenges due to FDA observations at CDMO sites. While these issues pose potential risks, the company's preparedness and strategic initiatives provide confidence in overcoming these hurdles.

Company Guidance -

Q3 2025

During the Scholar Rock Second Quarter 2025 Business Update Conference Call, the company provided extensive guidance on its strategic priorities and anticipated milestones. Scholar Rock is gearing up for the U.S. commercial launch of apitegromab for SMA, with a target action date of September 22, 2025, following its acceptance under priority review by the FDA. The company also plans a series of country launches, starting in Europe with Germany in 2026. Scholar Rock aims to expand apitegromab into additional rare neuromuscular diseases and invest in R&D with the initiation of the Phase II OPAL Trial for infants and clinical development in other neuromuscular indications by the end of 2025. Financially, Scholar Rock ended Q2 with $295 million, expecting additional funding from warrants and debt facilities, which extends their runway into 2027. The company is committed to disciplined capital allocation to support its commercial and development initiatives, anticipating monetizing its priority review voucher post-approval.

Regulatory and Commercial Progress for Apitegromab

The BLA for apitegromab has been accepted under priority review with a target action date of September 22. The company is preparing for a U.S. launch for SMA (spinal muscular atrophy) treatment and anticipates a European launch, starting with Germany in 2026.

Positive Clinical Trial Results

The SAPPHIRE trial showed statistically significant improvement in motor function for SMA patients treated with apitegromab. The EMBRAZE study met its primary endpoint, showing that apitegromab increased lean mass preservation by over 54% compared to tirzepatide alone.

Financial Stability and Strategic Investments

The company ended the quarter with $295 million. An additional $50 million is available under a debt facility, with a projected financial runway into 2027. The company is strategically investing in commercial readiness and pipeline expansion.

Global Launch Preparedness

Scholar Rock has fully staffed and deployed a U.S. customer-facing team to engage with SMA treatment centers, key opinion leaders, and payers. The company plans to reach patients globally, with an emphasis on targeting the unmet need for treatments that address muscle degeneration in SMA.

Scholar Rock Holding (SRRK) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SRRK Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 17, 2025	2025 (Q3)	-0.82 / -	-0.66	―	―	―
Aug 06, 2025	2025 (Q2)	-0.67 / -0.98	-0.6	-63.33% (-0.38)
May 14, 2025	2025 (Q1)	-0.68 / -0.67	-0.59	-13.56% (-0.08)
Feb 27, 2025	2024 (Q4)	-0.60 / -0.62	-0.498	-24.50% (-0.12)
Nov 12, 2024	2024 (Q3)	-0.58 / -0.66	-0.53	-24.53% (-0.13)	―
Aug 08, 2024	2024 (Q2)	-0.59 / -0.60	-0.47	-27.66% (-0.13)
May 07, 2024	2024 (Q1)	-0.48 / -0.59	-0.49	-20.41% (-0.10)	―	―
Mar 19, 2024	2023 (Q4)	-0.47 / -0.50	-0.44	-13.18% (-0.06)	―	―
Nov 07, 2023	2023 (Q3)	-0.50 / -0.53	-0.55	3.64% (+0.02)	―
Aug 09, 2023	2023 (Q2)	-0.53 / -0.47	-1.06	55.66% (+0.59)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SRRK Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$36.98	$34.62	-6.38%
May 14, 2025	$31.40	$30.54	-2.74%
Feb 27, 2025	$37.02	$35.96	-2.86%
Nov 12, 2024	$28.15	$26.66	-5.29%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Scholar Rock Holding (SRRK) report earnings?

Scholar Rock Holding (SRRK) is schdueled to report earning on Nov 17, 2025, After Close (Confirmed).

What is Scholar Rock Holding (SRRK) earnings time?

Scholar Rock Holding (SRRK) earnings time is at Nov 17, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is SRRK EPS forecast?

SRRK EPS forecast for the fiscal quarter 2025 (Q3) is -0.83.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing